Skip to main content

Table 2 Unadjusted incidence rates of venous thromboembolic events, before and after STS diagnosis

From: Older soft tissue sarcoma patients experience increased rates of venous thromboembolic events: a retrospective cohort study of SEER-Medicare data

n = 3,480 STSa patients

Incidence 12 months before STS diagnosis

Incidence 12 months after STS diagnosis

DVTa

 n/person-yearsb

137/3,418

367/2,468

 Rate/1,000c

40.1 (33.7–164.7)

148.7 (133.9–164.7)

 Rate ratio (after vs. before)d

–

3.7 (3.0–4.5)

PEa

 n/person-yearsb

34/3,463

105/2,589

 Rate/1,000c

9.8 (6.8–49.1)

40.6 (33.2–49.1)

 Rate ratio (after vs. before)d

–

4.1 (2.8–6.1)

OTEa

 n/person-yearsb

82/3,438

106/2,590

 Rate/1,000c

23.9 (19.0–49.5)

40.9 (33.5–49.5)

 Rate ratio (after vs. before)d

–

1.7 (1.3–2.3)

  1. Rate ratios are highlighted in italics.
  2. a VTE venous thromboembolic events, STS soft tissue sarcoma, DVT deep vein thrombosis, PE pulmonary embolism, OTE other thromboembolic event. OTE category includes the following diagnoses: central retinal vein occlusion, venous tributary (branch) occlusion, nonpyogenic thrombosis of intracranial venous sinus, phlebitis/thrombophlebitis of superficial vessels of lower extremities, phlebitis/thrombophlebitis of superficial veins of upper extremities, phlebitis/thrombophlebitis of other sites, gout with other specified manifestations, Budd–Chiari syndrome, and venous embolism/thrombosis of renal vein.
  3. b n number of VTE events, p-y person-years.
  4. cRates are per 1,000 person-years and are unadjusted. Age adjustment is unnecessary as these rates are intentionally representative of the older subpopulation (ages 65+) of STS patients. Only first VTE counted in rate estimates.
  5. dRate ratios are unadjusted.